Background
Ladiratuzumab is a humanized monoclonal antibody. It is currently being investigated for its potential in treating metastatic triple-negative breast cancer.
Product Details
| Reactivity | Human |
| Specificity | Detects human LIV-1/ZIP6 in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Ladiratuzumab. This product is for research use only. |
| Source | Recombinant Monoclonal Human IgG1 Clone #FB009 |
| Purification | Protein A/G purified from CHO cell culture supernatant |
| Immunogen | Human LIV-1/ZIP6 |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | 0.2 µm filtered solution in PBS |
| Applications | • ELISA: This antibody functions as an ELISA detection antibody for the specific antigen in direct ELISA. Colorimetric detection is performed after addition of a suitable substrate. |
| Reconstitution | Reconstitute at 0.5 mg/ml in sterile 1xPBS |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |